Lift Global Ventures Plc Regulatory News (LFT.PL)

20 September 2023

Lift Global Ventures Plc ("Lift" or the "Company") 

Investee Company Update

Lift Global Ventures Plc (AQSE:LFT), an investment company focused on financial media, technology and the energy sector, is pleased to announce that its investee company, Public Relations and Investor Relations company, Miriad Limited, has been appointed by Imperial Diagnostix Laboratories Limited as its Corporate Communications Agency. IDL is in the run up to a planned IPO in 2024, for which Miriad will be responsible for the distribution of all necessary documentation for potential investors to make an informed decision about the future of Imperial Diagnostix Laboratories Ltd and their possible and subsequent financial involvement.

Zak Mir, CEO Lift Global Ventures said, "We are delighted to welcome Imperial Diagnostix at such a key point in their journey towards IPO. IDL appreciate that in challenging markets, it is during the time of the fund raise when corporate communications and strategy are most important. Miriad looks forward to welcoming many other companies at similar stages in their development.

About Imperial Diagnostix Ltd:

Imperial Diagnostix Laboratories Ltd., a leading provider of diagnostic products and services, is pleased to share its recent accomplishments in August 2023. Firstly, they are pleased to announce that they have been granted access to the NHS supply chain in the UK, allowing them to extend their services and products to healthcare professionals across the nation.

Additionally, IDL has received certifications from the Ministry of Health (MHRA) in UK, CE certification in Europe and certification in Ghana, Nigeria and the UAE. In addition, they have successfully completed trials with partners in Mauritius, who will also represent The Seychelles, and Madagascar. These achievements mark a significant expansion of Imperial Diagnostix's global presence and further solidify their position in the Point of Care industry.

In summary, IDL stands as the UK's foremost provider of high-quality diagnostic solutions, delivering advanced Point of Care Testing (POCT) technologies to healthcare professionals. With a solid commitment to innovation and excellence, IDL intends to enhance patient outcome and support healthcare providers in expanding the parameters of In Vitro Fluorescence diagnostics globally.

IDL is already spearheading an initiative to support a government mandate to increase the number of diagnostic screening centres in the UK and by cultivating partnerships within practices and surgeries in both private and public healthcare sectors, they intend to support this initiative with their catalogue of cutting-edge diagnostic testing products.

Richard Paine Smith, CEO Imperial Diagnostix said, "As IDL have recently become aligned with the NHS Supply Chain, we will be targeting all of the National Health hospitals, clinics, surgeries and GPs to bring diagnostics and point of care to the source. In line with a government initiative, to reduce waiting times and expediting the availability to screen potentially life-threatening illnesses, IDL have the resources to fill the void for which the government have apparently allocated a budget of £1.6 Billion to, give the public control of their own health. In addition, IDL can identify how we can save the NHS considerable funds, increasing efficiency and potentially saving many lives.

About Miriad Ltd:

Miriad Limited, a financial PR and IR consulting company run by well-known stock market commentator and current Director, Zak Mir. Miriad provides a bespoke, personalised service to small/mid-cap entities in the UK and access to Zak's deep market insights, vast industry connections and significant social media including 24,000 on X (formerly Twitter).

Enquiries:

For more information please visit: www.liftgv.com